NeuroBo Pharmaceuticals Inc (NRBO):企業の財務・戦略的SWOT分析

◆英語タイトル:NeuroBo Pharmaceuticals Inc (NRBO) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1661
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥16,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥48,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

NeuroBo Pharmaceuticals Inc (NRBO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

NeuroBo Pharmaceuticals Inc (NeuroBo), formerly Gemphire Therapeutics Inc, is a clinical stage biopharmaceutical company that focuses on developing novel therapeutics for neurodegenerative and cardiometabolic diseases. The company pipeline product candidates include Gemcabene for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular diseases; NB-01 for painful diabetic neuropathy (PDN); and NB-02 for neurodegenerative diseases such as Alzheimer’s disease and tauopathies. The company has research facilities in South Korea. NeuroBo is headquartered in Boston, Massachusetts, the US.

NeuroBo Pharmaceuticals Inc Key Recent Developments

Jan 13,2020 NeuroBo Pharmaceuticals complete Gemphire merger
Aug 09,2019 Gemphire Therapeutics reports second quarter 2019 financial results and provides corporate update
Jul 25,2019 Gemphire to merge with NeuroBo Pharmaceuticals
Mar 15,2019 Gemphire Therapeutics reports fourth quarter and fiscal year 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
NeuroBo Pharmaceuticals Inc – Key Facts
NeuroBo Pharmaceuticals Inc – Key Employees
NeuroBo Pharmaceuticals Inc – Key Employee Biographies
NeuroBo Pharmaceuticals Inc – Major Products and Services
NeuroBo Pharmaceuticals Inc – History
NeuroBo Pharmaceuticals Inc – Company Statement
NeuroBo Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
NeuroBo Pharmaceuticals Inc – Business Description
NeuroBo Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
NeuroBo Pharmaceuticals Inc – Strengths
NeuroBo Pharmaceuticals Inc – Weaknesses
NeuroBo Pharmaceuticals Inc – Opportunities
NeuroBo Pharmaceuticals Inc – Threats
NeuroBo Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
NeuroBo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
NeuroBo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
NeuroBo Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 13, 2020: NeuroBo Pharmaceuticals complete Gemphire merger
Aug 09, 2019: Gemphire Therapeutics reports second quarter 2019 financial results and provides corporate update
Jul 25, 2019: Gemphire to merge with NeuroBo Pharmaceuticals
Mar 15, 2019: Gemphire Therapeutics reports fourth quarter and fiscal year 2018 financial results
Jan 09, 2019: NeuroBo to start trial of NB-01 for diabetic neuropathic pain
Jan 07, 2019: NeuroBo selects AiCure to advance pivotal neuropathic pain clinical trial
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
NeuroBo Pharmaceuticals Inc, Key Facts
NeuroBo Pharmaceuticals Inc, Key Employees
NeuroBo Pharmaceuticals Inc, Key Employee Biographies
NeuroBo Pharmaceuticals Inc, Major Products and Services
NeuroBo Pharmaceuticals Inc, History
NeuroBo Pharmaceuticals Inc, Subsidiaries
NeuroBo Pharmaceuticals Inc, Key Competitors
NeuroBo Pharmaceuticals Inc, Ratios based on current share price
NeuroBo Pharmaceuticals Inc, Annual Ratios
NeuroBo Pharmaceuticals Inc, Annual Ratios (Cont...1)
NeuroBo Pharmaceuticals Inc, Interim Ratios
NeuroBo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
NeuroBo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
NeuroBo Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
NeuroBo Pharmaceuticals Inc, Performance Chart (2015 - 2019)
NeuroBo Pharmaceuticals Inc, Ratio Charts
NeuroBo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
NeuroBo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[NeuroBo Pharmaceuticals Inc (NRBO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MidAmerican Energy Co:電力:M&Aディール及び事業提携情報
    Summary MidAmerican Energy Company (MidAmerican Energy), a subsidiary of Berkshire Hathaway Energy, is a regulated electric and natural gas utility company that carries out the generation, transmission and distribution and selling of electricity. The company also undertakes distribution, selling and …
  • Empresas Publicas De Medellin ESP:電力:M&Aディール及び事業提携情報
    Summary Empresas Publicas De Medellin ESP (EPM) is a decentralized body, operational under the ownership of Medellin municipality. It generates, transmits, and distributes electricity as well as undertakes gas distribution, wastewater and garbage treatment, and telecommunications services across the …
  • Trust International Insurance Co. P.L.C.:企業の戦略・SWOT・財務分析
    Trust International Insurance Co. P.L.C. - Strategy, SWOT and Corporate Finance Report Summary Trust International Insurance Co. P.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • SuppreMol GmbH-製薬・医療分野:企業M&A・提携分析
    Summary SuppreMol GmbH (SuppreMol), a subsidiary of Baxalta Inc, is a biopharmaceutical company that develops therapeutics in the areas of autoimmune, chronic inflammatory diseases, and allergies. The company’s lead drug candidate is extensively profiled in in-vitro, ex-vivo and in-vivo experiments. …
  • KT&G Corp:企業の戦略・SWOT・財務情報
    KT&G Corp - Strategy, SWOT and Corporate Finance Report Summary KT&G Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • L E Pritchitt & Co Ltd. :企業の戦略・SWOT・財務情報
    L E Pritchitt & Co Ltd. - Strategy, SWOT and Corporate Finance Report Summary L E Pritchitt & Co Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • WESCO International, Inc.:企業の戦略・SWOT・財務情報
    WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report Summary WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Merrimack Pharmaceuticals Inc (MACK):製薬・医療:M&Aディール及び事業提携情報
    Summary Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers. The company’s marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (mark …
  • Airvolution Energy Limited:電力:M&Aディール及び事業提携情報
    Summary Airvolution Energy Limited (Airvolution) a subsidiary of Electricity Supply Board, is a renewable energy company that develops, construct and operate small onshore wind projects. It provides landowners a secure, long term revenue stream and takes all the financial risk during development of …
  • MKS Instruments Inc (MKSI):企業の財務・戦略的SWOT分析
    MKS Instruments Inc (MKSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Russian Reinsurance Company
    Russian Reinsurance Company - Strategy, SWOT and Corporate Finance Report Summary Russian Reinsurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Honkarakenne Oyj (HONBS):企業の財務・戦略的SWOT分析
    Honkarakenne Oyj (HONBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Taiwan Semiconductor Manufacturing Company Limited:企業の戦略・SWOT・財務分析
    Taiwan Semiconductor Manufacturing Company Limited - Strategy, SWOT and Corporate Finance Report Summary Taiwan Semiconductor Manufacturing Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Atomenergoprom:企業の戦略的SWOT分析
    Atomenergoprom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Tullow Oil plc:戦略・SWOT・企業財務分析
    Tullow Oil plc - Strategy, SWOT and Corporate Finance Report Summary Tullow Oil plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Samsung C&T Corp:企業のM&A・事業提携・投資動向
    Samsung C&T Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Samsung C&T Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Harvey Norman Holdings Ltd (HVN):企業の財務・戦略的SWOT分析
    Harvey Norman Holdings Ltd (HVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • TG Therapeutics Inc (TGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the tr …
  • TAXIS Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary TAXIS Pharmaceuticals Inc (TAXIS Pharma) is a biopharmaceutical company that treats, reduce and eliminates the threat of current and emergent antimicrobial resistance across a range of infectious diseases. It research new classes of antibiotic agents to treat life-threatening and multidrug-r …
  • Attijari Bank SA:企業の戦略・SWOT・財務分析
    Attijari Bank SA - Strategy, SWOT and Corporate Finance Report Summary Attijari Bank SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆